ESMO 2017: Prostate Cancer Highlights

(Length of discussion ~ 36 minutes)

Thomas Keane reviews recent data presented at the ESMO 2017 conference focusing on advanced prostate cancer and the addition of abiraterone to androgen deprivation therapy as well as the results of the STAMPEDE and LATITUDE trials. Highlighting a number of presentations, he focuses on one in particular “Adding abiraterone acetate plus prednisone or docetaxel for patients with high risk prostate cancer starting long-term androgen deprivation therapy".  These presentations address abiraterone earlier on in the disease and the role flutamide plays in the treatment of PCa. He shares his final thoughts on the question of the use of these two compounds versus docetaxel in terms of progression and survival and how it relates to availability and cost

Additional Content on Prostate Cancer coverage from ESMO 2017

ESMO 2017: Adding abiraterone acetate plus prednisolone or docetaxel for patients with high-risk prostate cancer starting long-term androgen deprivation therapy: directly randomized data from STAMPEDE

ESMO 2017: Adding abiraterone for patients with high-risk prostate cancer (PCa) starting long-term ADT: Outcomes in non-metastatic (M0) patients from STAMPEDE

ESMO 2017: Outcomes of Prechemotherapy Abiraterone Acetate or Enzalutamide for mCRPC after ADT + Docetaxel or ADT alone for mHSPC

ESMO 2017: Indirect Comparison of Abiraterone Acetate and Docetaxel for Treatment of Metastatic “Hormone-Sensitive” Prostate Cancer


Biography:

Thomas E. Keane, MBBCh, FRCSI, FACS